You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report

Article info

Article menu

This article has a correction. Please see:

Download PDFPDF

XML
Case report
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report

Authors

  • Angelo Dipasquale Department of Medical Oncology and Hematology, IRCCS Humanitas Research Hospital, Milan, Italy Department of Biomedical Sciences, Humanitas University, Milan, Italy PubMed articlesGoogle scholar articles
  • Pasquale Persico Department of Medical Oncology and Hematology, IRCCS Humanitas Research Hospital, Milan, Italy Department of Biomedical Sciences, Humanitas University, Milan, Italy PubMed articlesGoogle scholar articles
  • Elena Lorenzi Department of Medical Oncology and Hematology, IRCCS Humanitas Research Hospital, Milan, Italy Department of Biomedical Sciences, Humanitas University, Milan, Italy PubMed articlesGoogle scholar articles
  • Daoud Rahal Department of Pathology, IRCCS Humanitas Research Hospital, Milan, Italy PubMed articlesGoogle scholar articles
  • Armando Santoro Department of Medical Oncology and Hematology, IRCCS Humanitas Research Hospital, Milan, Italy Department of Biomedical Sciences, Humanitas University, Milan, Italy PubMed articlesGoogle scholar articles
  • Matteo Simonelli Department of Medical Oncology and Hematology, IRCCS Humanitas Research Hospital, Milan, Italy Department of Biomedical Sciences, Humanitas University, Milan, Italy PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Matteo Simonelli; matteo.simonelli{at}hunimed.eu
View Full Text

Citation

Dipasquale A, Persico P, Lorenzi E, et al
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report
Journal for ImmunoTherapy of Cancer 2021;9:e001870. doi: 10.1136/jitc-2020-001870

Publication history

  • Accepted December 20, 2020
  • First published February 11, 2021.
Online issue publication 
January 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.